Article thumbnail

Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma

By Erik F. Hensen and Jean-Pierre Bayley

Abstract

The last 10 years have seen enormous progress in the field of paraganglioma and pheochromocytoma genetics. The identification of the first gene related to paraganglioma, SDHD, encoding a subunit of mitochondrial succinate dehydrogenase (SDH), was quickly followed by the identification of mutations in SDHC and SDHB. Very recently several new SDH-related genes have been discovered. The SDHAF2 gene encodes an SDH co-factor related to the function of the SDHA subunit, and is currently exclusively associated with head and neck paragangliomas. SDHA itself has now also been identified as a paraganglioma gene, with the recent identification of the first mutation in a patient with extra-adrenal paraganglioma. Another SDH-related co-factor, SDHAF1, is not currently known to be a tumor suppressor, but may shed some light on the mechanisms of tumorigenesis. An entirely novel gene associated with adrenal pheochromocytoma, TMEM127, suggests that other new paraganglioma susceptibility genes may await discovery. In addition to these recent discoveries, new techniques related to mutation analysis, including genetic analysis algorithms, SDHB immunohistochemistry, and deletion analysis by MLPA have improved the efficiency and accuracy of genetic analysis. However, many intriguing questions remain, such as the striking differences in the clinical phenotype of genes that encode proteins with an apparently very close functional relationship, and the lack of expression of SDHD and SDHAF2 mutations when inherited via the maternal line. Little is still known of the origins and causes of truly sporadic tumors, and the role of oxygen in the relationships between high-altitude, familial and truly sporadic paragangliomas remains to be elucidated

Topics: Article
Publisher: Springer Netherlands
OAI identifier: oai:pubmedcentral.nih.gov:3100491
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas.
  2. (2009). An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.
  3. (1993). Analysis of a second family with hereditary non-chromaffin paragangliomas locates the underlying gene at the proximal region of chromosome 11q.
  4. (2010). Are we overestimating the penetrance of mutations in SDHB? Hum Mutat 31:761–762
  5. (1997). Atlas of tumor pathology: tumors of the adrenal gland and extra-adrenal paraganglia.
  6. (1992). Bardoel A et al
  7. Bayley JP et al (2009) SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma.
  8. Cascon A et al (2005) Epigenetic analysis of
  9. (2004). Chromosome 11 monosomy in conjunction with a mutated SDHD initiation codon in nonfamilial paraganglioma cases.
  10. (1976). Chronic hypoxia and chemodectomasinbovinesathighaltitudes.ArchPatholLabMed100:636–639
  11. Cirami C et al (2007) Genetic screening for pheochromocytoma: should SDHC gene analysis be included?
  12. (2009). Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients.
  13. (2009). Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out.
  14. (2006). Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.
  15. de Montpreville V et al (2008) Paraganglioma after maternal transmission of a succinate dehydrogenase gene mutation.
  16. Decaluwe H et al (2001) Molecular characterization of a pediatric pheochromocytoma with suspected bilateral disease.
  17. Diepvens F et al (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.
  18. (2001). Differential loss of chromosome 11q in familial and sporadic parasympathetic paragangliomas detected by comparative genomic hybridization.
  19. et al (2010) SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma.
  20. (2006). Expression of HIF-1 alpha, HIF-2 alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.
  21. (2008). Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nat Clin Pract Endocrinol Metab
  22. (2010). Familial neonatal isolated cardiomyopathy caused by a mutation in the flavoprotein subunit of succinate dehydrogenase.
  23. (1981). Familiar non-chromaffinic paragangliomas (glomus tumors). Clinical and genetic aspects (abridged).
  24. (2004). Founder mutations among the Dutch.
  25. (2002). Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma.
  26. (1994). Further localization of the gene for hereditary paragangliomas and evidence for linkage in unrelated families.
  27. Gempel K et al (2006) Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA).
  28. (2001). Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.
  29. (2006). Genetic analysis of high altitude paragangliomas. Endocr Pathol 17:201–202
  30. (1989). Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory.
  31. (2010). Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.
  32. Giacche M et al (2009)ClinicallyguidedgeneticscreeninginalargecohortofItalian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas.
  33. (2006). Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: a possible hot spot? Genes Chromosom Cancer 45:213–219
  34. Heales SJ et al (2006) Phenotypic variability of mitochondrial disease caused by a nuclear mutation in complex II.
  35. Hes FJ et al (2009) Molecular characterization of novel germline deletions affecting SDHD and SDHC in pheochromocytoma and paraganglioma patients.
  36. (1973). High altitude hypoxia and chemodectomas.
  37. (2008). Hypoxia signalling through mTOR and the unfolded protein response in cancer.
  38. (2010). Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types.
  39. (1979). Inactivation of succinate dehydrogenase by 3-nitropropionate.
  40. (2007). Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates—possible links between cell metabolism and stabilization of HIF.
  41. Klopstock T et al (2009) SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy.
  42. Kozupa A et al (2009) Penetrance and clinical consequences of a gross SDHB deletion in a large family.
  43. Kunst HP et al (2009) The first Dutch SDHB founder deletion in paraganglioma-pheochromocytoma patients.
  44. Lorenzato A et al (2005) Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions.
  45. (2010). Low penetrance of a SDHB mutation in a large Dutch paraganglioma family.
  46. McWhinney SR et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.
  47. Muljono A et al (2010) Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
  48. (2004). Multiprotein complex containing succinate dehydrogenase confers mitochondrial ATP-sensitive K? channel activity.
  49. Munnich A et al (2000) Compound heterozygous mutations in the flavoprotein gene of the respiratory chain complex II in a patient with Leigh syndrome.
  50. (2010). Mutation of SDHB is a cause of hypoxia-related high-altitude paraganglioma.
  51. (2010). Mutations of the metabolic genes IDH1, IDH2, and SDHAF2 are not major determinants of the pseudohypoxic phenotype of sporadic pheochromocytomas and paragangliomas.
  52. Myssiorek D et al (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma.
  53. (2001). Nearly all hereditary paragangliomas in The Netherlands are caused by two founder mutations in the SDHD gene.
  54. (2009). Phaeochromocytomas and sympathetic paragangliomas.
  55. (2008). Pheochromocytoma and extra-adrenal paraganglioma: updates.
  56. (2006). Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor
  57. RopersHH(1995)Finemappingofaputativelyimprintedgenefor familial non-chromaffin paragangliomas to chromosome 11q13.1: evidence for genetic heterogeneity.
  58. (2010). SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet
  59. (2003). SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology.
  60. (2006). Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer.
  61. (2005). Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase.
  62. Taschner PEM et al (2004) Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families.
  63. (1969). The carotid body at high altitudes.
  64. (1971). The carotid body in animals at high altitude.
  65. (2008). The H19 locus acts in vivo as a tumor suppressor.
  66. (1973). The human carotid body at high altitudes. Pathol Microbiol
  67. (2005). The SDH mutation database: an online resource for succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and mitochondrial complex II deficiency.
  68. Vriends AH et al (2010) The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family.
  69. (2010). Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?
  70. Zwinderman AH et al (2000) Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal.